Sc in prion disorders, are known to re-fold and assemble into highly organized fibrils, which associate with heparan sulfate (HS) proteoglycans to form tissue deposits called amyloid. Mononuclear phagocytes have long been thought to be involved in this process, and we describe a monocytic cell culture system that can transform the acute-phase protein serum amyloid A (SAA1.1) into AA-amyloid and appears to recapitulate all the main features of amyloidogenesis observed in vivo. These features in common include nucleation-dependent kinetics, identical proteolytic processing of SAA1.1, and co-deposition of HS with the fibrils. Heparin and polyvinylsulfonate previously reported to block AAamyloidogenesis in mice are also effective inhibitors in this cell culture model. Furthermore, a synthetic peptide (27-mer) corresponding to a HS binding site of SAA, blocks amyloid deposition at a concentration that is several-orders-of-magnitude lower than any other peptide-based inhibitor previously reported. The 27-mer's inhibitory activity may target the amyloidogenic pathway specifically as it does not interfere with the binding of SAA to monocytes. These data provide direct evidence that SAA1.1:HS interactions are a critical step in AA-amyloidogenesis and suggest a novel treatment strategy for other amyloidoses.
During the early 1980s heparan sulfate (HS), a glycosaminoglycan (GAG) found ubiquitously on cell surfaces and in the extracellular matrix, was shown to co-deposited both temporally and spatially with the AA-fibrils in the spleen (8) (9) (10) . A survey of different types of amyloids, including Aβ (11, 12) , AL (immunoglobulin light chain deposits; 13), TTR (transthyretin; familial amyloidotic polyneuropathy; 14), Cystatin C (hereditary cerebral hemorrhage; 15), IAPP (islet amyloid precursor polypeptide seen in 95% of type-II diabetes; 16), and PrP Sc (Prion disease; 17) , revealed that HS is a universal component of amyloid in situ. Several studies have demonstrated that HS is not simply an inert component of amyloid but plays a mechanistic role in its genesis. HS and no other GAG tested (heparin, chondroitin sulfate) can increase the β-sheet content of murine SAA 1.1 (the prevalent conformation of amyloid fibrils), leaving the non-amyloidogenic 2.1 isoform unaffected (18) . An HS-dependent shift in structure from random coil to β-sheet has also been observed for Aβ (19) , which precedes its rapid assembly into fibrils (20, 21) . The ability of HS to promote fibrillogenesis in vitro has also been reported for IAPP (22) , α-synuclin (generates Lewy bodies in Parkinson's disease; 23) and phosphorylated tau protein, which forms the amyloid-like paired helical-filaments of neurofibrillary tangles in AD (24) . We and others have postulated that the amyloid-promoting activity of HS is facilitated through specific amyloid polypeptide:HS interactions via binding sites. Such binding sites have been identified for Aβ (25, 26) , prion protein (27, 28) , IAPP (29) , β-2-microglobulin (amyloid associated with chronic renal dialysis) (30, 31) , immunoglobulin light chain (32) , and SAA (33) .
Investigations into the mechanism of amyloidogenesis have been performed either by using in vitro systems to study fibril assembly of isolated and synthetic amyloidogenic polypeptides, or by examination of amyloids in situ, from human and animal sources. In vitro studies frequently use non-physiological conditions for fibrillogenesis and fail to study biological factors promoting amyloidogenesis, while analysis of in vivo systems are hampered by a lack of control over a large number of potential variables. A cell culture model provides a bridge between these two systems, and in this report we describe a monocytic cell culture system that appears to recapitulate all the main features of amyloidogenesis. It has also allowed us to demonstrate that a synthetic peptide (27-mer) , corresponding to the HS binding site of SAA1.1 (33) , is a potent inhibitor of amyloidogenesis and provides direct evidence for the role of HS in the disease process. The anti-amyloid activity of this 27-mer appears to be far more potent than other peptide-based inhibitors previously reported (34) (35) (36) (37) , suggesting that anti-amyloid strategies based on the HS binding sequences for other amyloid polypeptides such as Aβ or IAPP, may be highly successful.
MATERIALS AND METHODS

J774A.1 Cell culture
The murine monocytic cell line J774A.1 (American Type Culture Collection, Manassas, VA) was cultured in RPMI (Sigma, St. Louis, MO) media, which contained 25 mM HEPES, 15% fetal bovine serum (FBS), and 50 µg/ml penicillin-streptomycin, at 37°C, 5% CO 2. The cell stocks were passaged every four days, and the media replaced every other day. Cells were seeded at a minimal density in 8-well chamber slides (Lab-Tek®, Nalge Nunc International, Naperville, IL) in 350 µl medium/well and allowed to reach ~80-90% confluence (3 days), ~2.2 × 10 5 cells per well. To induce AA-amyloidogenesis, cells were treated for 24 h with 10 µg of AEF in the culture media, then the medium was removed and the cells were rinsed with fresh media. To these cells 350 µl of medium was added, containing either 0.3 mg/ml HDL-SAA, HDL, 0.05 mg/ml SAA1.1, or SAA2.1, and replenished every 2 days for 7 days. At the end of the treatment period the cells were either stained with Congo red to visualize the amyloid deposits or the cells were dissolved in 1% NaOH and assayed for amyloid fibrils by thioflavin-T fluorescence (38) . In some experiments, native heparin (Sigma), low-molecular-weight heparin (Sigma), chondroitin sulfate, polyvinylsulfonate, or synthetic peptides were included at different concentrations throughout the HDL-SAA treatments. Some wells containing amyloid were digested with either, 200 mU Chondroitinase ABC (Sigma) /well, or 2 mU/well each of heparinase and heparatinase (Seikagaku America, Ijamsville, MD) in PBS, 2 mM CaCl 2 incubated for 4 h at 37°C.
HDL-SAA and purification of delipidated SAA
Plasma HDL-SAA concentrations were experimentally elevated in CD1 mice (Charles Rivers, Montreal, Quebec, Canada) by a subcutaneous injection of 0.5 ml of 2% (w/v) AgNO 3 producing a sterile abscess. After 18-20 h, mice were killed by CO 2 narcosis and exsanguinated by cardiac puncture. HDL-SAA was isolated by sequential density flotation as described previously (39) . SAA1.1 and 2.1 were isolated from HDL-SAA denatured with 6 M guanidine-HCl then purified by reversed-phase high-performance liquid chromatography on a semipreparative C-18 Vydac column connected to a Waters (Millipore) HPLC system (33) . Each isoform makes up ~16.7% of total HDL-SAA protein.
AEF preparation
AEF was prepared as AA-amyloid fibrils as described previously (5) . Amyloid-laden mouse spleens were homogenized in 0.9% NaCl using a polytron homogenizer (10-20 s pulses) then centrifuged at 10,000 x g for 30 min. The supernatant was discarded and the tissue residue was re-extracted 10-12 times until the absorbance of the supernatant was less than 0.1 (280 nm). The remaining residue was suspended in water and centrifuged at 18,000 rpm (Ti50.2 rotor) for 1 h, and the pellet was resuspended and pelleted again. The second supernatant containing the AEF was frozen in aliquots and stored at -20°C. AEF activity was evaluated biologically in a murine model of AA-amyloidosis. To initiate AA-amyloidosis, mice were co-injected with 0.2 ml AEF (0.5 mg/ml) and 0.5 ml 2% silver nitrate subcutaneously, which produces an inflammatory response that elevates SAA expression. After 5 days, the spleens were harvested and the tissue was prepared and assessed for amyloid as described in Kisilevsky et al. (40) .
Amyloid detection and quantitation
Congo Red staining for amyloid was performed on cells that were rinsed with PBS, fixed for 10 min in 70% ethanol, and then stained for 45 min. with Congo red prepared in alkaline 80% ethanol, NaCl saturated solution. After counter-staining with hematoxylin, slides were dehydrated with ethanol, washed with Citrisolv (Fisher), and prepared with Permount (Fisher) and a coverslip. Alcian Blue 8GX (0.45%) and sodium sulfate (0.45%) in 10% acetic acid (SAB) were used to stain sulfated polysaccharides, followed by counter-staining with VanGiesen stain (1% acid fuchsin in 3% picric acid). Quantitation of amyloid was performed by thioflavin-T (Th-T) fluorescence (38) . Fluorescence spectra of Th-T were acquired at 25°C with a Spectra Max Gemini 96-well plate reader. Cells were solubilized in 1% NaOH, which was then neutralized (pH 7) and added to 6.25 µL of 2.5 mM Th-T (Sigma) in PBS. Control spectra of Th-T and cell extract alone were determined. The emission spectra were collected by exciting samples at 440 nm (slit width, 10 nm) then monitoring the emissions at 482 nm (slit width, 10 nm).
Western blot analysis of AA-amyloid and SAA binding to J774 cells in the presence of inhibitors
Amyloid-laden spleens or J774 cells were solubilized in SDS-loading buffer and separated by PAGE (41) . Proteins were transferred electrophoretically from the gel to Immobilon-P membrane (Millipore) at 100V for 1 h at 4°C in 25 mM Tris-HCl, 192 mM glycine, 10% methanol, pH 8.3. Membranes were blocked with 6% skim milk powder then incubated with affinity-purified polyclonal anti-SAA antibody (1:1000 dilution). Bands were visualized by chemiluminescence by using the ECL Western blotting detection system as per instructions (Amersham).
RESULTS
J774A.1 cells mediated conversion of native HDL-SAA to AA-amyloid deposits
Chamber slides were seeded with murine monocytic cells (J774A.1) in RPMI medium + 15% (v/v) FBS, and at 80% confluence 30 µg/ml AEF was added to the medium for 24 h and then replaced with fresh medium supplemented with 0.3 mg/ml HDL-SAA. After 7 days, replenishing the J774 cells with HDL-SAA in fresh medium every 48 h, significant quantities of amyloid were detected by Congo red (CR) staining (Fig. 1A) and thioflavin T fluorescence (Th-T; Fig. 1D ). Treatment of the J774 cells with AEF for as little as 6 h was sufficient to initiate amyloid formation in the presence of HDL-SAA (data not shown). J774 cells incubated with HDL-SAA alone produced much less amyloid, indicating that AEF greatly accelerated amyloidogenesis (Fig. 1B, light-green spots) . AEF, which contains some amyloid fibrils, did not affect cell growth or contribute to the CR staining (Fig.  1C) . As amyloid accumulated cell numbers became reduced with most of the J774 cells surrounding the extracellular amyloid deposits. Also amyloidogenesis required viable cells because fixation with formaldehyde prior to the amyloid induction protocol produced no amyloid (data not shown).
Using Th-T fluorescence, the kinetics of amyloid deposition in both cell culture and mouse spleens was monitored for 7 days post-AEF administration (Fig. 1D) . Both appeared to follow the same kinetics with amyloid detected as early as 24 h after the addition of HDL-SAA in culture or induction of amyloidosis in the mice. Amyloid deposition increased linearly for 6 days, at which time it appears to plateau. Based on total protein content, amyloid deposition was 54-fold greater in cell culture than in spleens. The absence of AEF in cell culture delayed (5 days) the production of detectible amyloid (Fig. 1D, open circles) .
SAA isoform preference and fibril processing are identical to that in vivo
Mice, like humans, express two major isoforms of SAA (SAA1.1 and SAA2.1) during an acutephase response, but in mice only SAA1.1 (SAA2 old nomenclature) is deposited as AA-amyloid (42, 43) . To determine whether this was also the case in cell culture, J774 cells were incubated with AEF and either purified SAA1.1 or SAA2.1 at 50 µg/ml (equivalent to their respective concentrations in plasma HDL-SAA), HDL-SAA, or HDL reconstituted with SAA1.1 or SAA2.1. The wells were then stained with CR for a qualitative assessment (not shown) or assayed by ThT fluorescence (Fig. 2A) . Only SAA1.1 produced amyloid but in much reduced quantity (9% of HDL-SAA), whereas no amyloid was detected with SAA2.1. When purified SAA1.1 or 2.1 were first re-associated with HDL, the resulting amyloid load with the reconstituted HDL-SAA1.1 was close to the amount assayed for native HDL-SAA. Reconstituted HDL-SAA2.1 produced no amyloid. AA-amyloid fibrils in vivo are composed primarily of a set of peptides spanning the amino two-thirds of SAA1.1. Western blot analysis of cell culture amyloid probed with anti-SAA antibody showed that the proteolytic fragmentation of SAA1.1 appeared to be identical between cell culture and mouse splenic AA-amyloid (Fig. 2B) .
HS, but not chondroitin or dermatan sulfate, co-deposit with amyloid
Of the six major GAGs (dermatan sulfate, chondroitin sulfate, keratan sulfate, heparin, HS, and hyauronan) only HS has been shown to be a universal component of amyloids. Hence, we determined which GAG, if any, was associated with the cell culture amyloid. Intense staining of cell culture amyloid was observed with sulfated alcian blue (SAB), indicating a high sulfated GAG content (Fig. 3A) . To distinguish between the different sulfated GAG species, wells containing amyloid were incubated with either a combination of heparinase/ heparatinase, which specifically eliminates HS, or chondroitinase ABC, which digests chondroitin and dermatan sulfate. Amyloid deposits treated with the HS lyases showed no staining with SAB, although the residual amyloid deposits could still be discerned (Fig. 3B) . Chondroitinase ABC-treated wells still exhibited strong SAB staining (data not shown), further indicating that most GAG associated with the amyloid fibrils was HS.
Heparin and polyvinylsulfonate inhibit amyloid deposition
To examine whether sulfated-GAGs are involved in the generation of the cell culture amyloid, we tested the ability of native heparin (N-hep), low-molecular-weight heparin (LMW-hep) chondroitin sulfate (CS), and polyvinylsulfonate (PVS) to inhibit amyloidogenesis (Fig. 4) . Clinically relevant doses of LMW-hep administered to mice undergoing AA-amyloidosis has been reported to reduce the amyloid-load (44). We found that both N-hep and LMW-hep could inhibit the process of amyloidogenesis in cell culture. LMW-hep was well tolerated by the cells, but at higher concentrations N-hep became toxic. Even at high concentrations, chondroitin sulfate was unable to affect amyloid deposition. PVS, a low-molecular-weight anionic polymer containing structural features of sulfated GAGs, could achieve 50 and 100% inhibition at 0.5 and 9 µM, respectively. The anti-amyloid property of PVS has been demonstrated previously in vivo (40) .
A synthetic peptide corresponding to SAA1.1's HS binding site is highly anti-amyloidogenic
We have identified a heparin/HS binding site on the C-terminal end of SAA1.1 (77-ADQEANRHGRSGKDPNYYRPPGLPAKY-103) (33) and have postulated that an interaction between this 27-mer sequence and HS promotes SAA1.1 fibrillogenesis. To test this hypothesis, we attempted to block SAA1.1:HS interactions during amyloidogenesis by incubating the J774 cells with increasing concentrations of a synthetic 27-mer (Fig. 5A) . Quantitation of the amyloid-loads at the end of the induction protocol revealed that the 27-mer was a profound inhibitor of amyloidogenesis with an IC 50 of 0.02 µM, which is 25-fold lower than for PVS. This effect was sequence-specific. Scrambling the 27-mer's sequence (PLPAQGKPGPDHYARNDSYAKNRYERG) or replacing residues R83, H84, and R86 with A, which destroys HS binding (33) , caused a complete lost of inhibitory activity. Both heparin and PVS prevented HDL-SAA binding to J774 cells, which is likely responsible for their anti-amyloid activities (Fig.  5B) . However, the 27-mer did not interfere with HDL-SAA binding to J774 cells, suggesting that the amyloidogenic pathway was being blocked downstream of the cell surface binding event (Fig. 6 ).
DISCUSSION
Mononuclear phagocytes (macrophage, microglia, Kupffer cells) have long been suspected of being directly involved in the process of amyloidogenesis. They are often found in close proximity to amyloid deposits as in, AA-amyloid (45, 46), β-2-microglobulin (47), Aβ amyloid (48, 49) , and Prion amyloid (50, 51) . Aβ (52, 53) and AA-amyloid fibrils (54) have also been observed in cytoplasmic vesicles of macrophage, although it was unclear whether fibril assembly or degradation was taking place. However, Kluve-Beckerman and co-workers (55) have reported that peritoneal cells and a transformed peritoneal-macrophage cell line (IC-21 cells) could produce AA-amyloid when cultured for up to two weeks with AEF and bacterially expressed delipidated SAA. We have found that selective reduction of splenic macrophage in mice by treatment with clodronate (dichloromethylene diphosphonate; 56, 57) greatly impeded AA-amyloidogenesis (manuscript in preparation). Thus, we chose a well-characterized monocytic cell line to develop a physiologically relevant model for amyloidosis that would allow us to investigate the mechanism of amyloidogenesis in greater detail and aid in the identification of effective amyloid inhibitors.
SAA as a pure, delipidated, protein poses significant experimental difficulties because it is extremely hydrophobic and prone to denaturation and aggregation in solution. To overcome this problem, we incubated J774 cells with SAA in its native state/conformation, associated with HDL. We found that native HDL-SAA, or reconstituted HDL-SAA1.1, produced 11-fold more amyloid than delipidated SAA. This result suggested that the pre-amyloidogenic conformation of SAA is critical for refolding and assembly into fibrils and that a lipid microenvironment was necessary for this process. Evidence indicates that both these factors play a role in the development of other types of amyloid as well. For TTR (58, 59 ) and insulin (60) , the degree of denaturation greatly influences the efficiency of their fibrillogenesis with partially denatured intermediates generating appreciably more fibrils than those more extensively denatured. Also the fibrillogenesis of Aβ (61, 62) and prion protein (63) (64) (65) has been reported to occur optimally on bilayer lipid surfaces or in cholesterol-rich microdomains.
The main features described for AA-amyloidogenesis in vivo appear to be recapitulated in cell culture. The kinetics of deposition converting native-SAA into fibrils, proteolytic processing, and co-deposition of HS, a universal component of all types of amyloids observed in cell culture, appear identical to those in vivo. This finding suggests that some or all of the steps in AA-amyloidogenesis, including SAA dissociation from HDL, re-folding, assembly, proteolytic processing, and the codeposition of HS with AA-amyloid, are mediated by monocytic cells. Furthermore, the rate of amyloid deposition relative to total protein was ~54-fold greater in cell culture than in mouse spleens, again indicating that all the important factors required for amyloidogenesis were contained within this cell culture system. A sulfonate, PVS (40) , and heparin (44) have been reported to prevent amyloid deposition in mice and were also found to be effective in cell culture. Both could block HDL-SAA binding to macrophage probably by competing for cell surface HS binding sites. Murine HDL and HDL-SAA have been found to bind macrophage in a HS-dependent manner (66), likely involving apo-E, which contains two well-described HS binding sites (67) (68) (69) . It is unknown whether the HS binding site of SAA (33) contributes to the overall binding of HDL-SAA to macrophage.
Heparin and to a lesser extent PVS have structural similarities to HS. The biosynthesis of HS and heparin involves the sequential addition of N-acetylglucosamine (GlcNac) and β-D-glucuronic acid (GlcA; 70, 71), which then undergoes further enzymatic modifications, including N-deacetylation, epimerization at the C-5 position of GlcA converting it to iduronic acid (IdoA), and sulfation. For HS these reactions are incomplete, producing a varied structure with ≤ 50% IdoA with regions of low and high sulfation (0.2 to 2 sulfates/disaccharide). For heparin the modifications are more complete, resulting in a homogeneous chain containing ~90% IdoA and 2-3 sulfates per disaccharide, which closely resembles highly sulfated oligosaccharide sequences of HS. Due to its high net negative charge and ubiquitous expression, HS can associate with a variety of proteins (72) . These interactions have profound physiologic importance since they modulate the function of numerous proteins, such as growth factors, serine protease inhibitors, extracellular matrix proteins, plasma lipoproteins, and lypolytic enzymes. Many of these protein:HS interactions, such as with, antithrombin III(73), FGF-2 (74, 75) , and PDGF-Achain (76) , are dependent on specific HS oligosaccharide sequences.
Further evidence that AA-amyloidogenesis was dependent on SAA-HS interactions was provided with a synthetic peptide (27-mer) , which corresponds to the HS binding site of SAA 1.1 (33) . It was found to be a potent inhibitor of amyloidogenesis with an IC 50 of 20 nM, which is 25-fold lower than that of PVS (IC 50 = 500 nM). Surprisingly, unlike heparin and PVS, the 27-mer did not appear to interfere with the normal binding of HDL-SAA to macrophage, for which there may be as many as 55,000 binding sites/cell (77) . It is possible that SAA-HS interactions do not contribute to HDL-SAA binding of macrophage, which instead, are mediated by other apo-proteins such as apoE. Another region of SAA1.1 has recently been identified as the ligand for a SAA cell surface receptor (manuscript in preparation), and we are currently investigating its role in amyloidogenesis. We propose that the 27-mer sequence is involved in the amyloidogenic pathway downstream of the cell surface binding event (Fig. 6) , which would include: 1) dissociation of SAA1.1 from HDL; 2) refolding to increase its β-sheet content; 3) oligomerization/fibrillogenesis; and 4) proteolytic processing of SAA1.1. The latter step probably takes place after SAA1.1 is incorporated into AAfibrils and is not directly involved in AA-amyloidogenesis (78-80).
Numerous reports have described the ability of short peptides to inhibit Aβ and IAPP fibrillogenesis in vitro. In a cell-free system, an Aβ peptide (residues 16-20) at 100 µM has been shown to associate with Aβ1-40 and prevent fibril assembly (34, 35) . Short IAPP peptides (residues 20-25 and 24-29), at a 10-fold molar excess (100 µM) over IAPP, could also reduce the amyloid loads in vitro, by 80 to 85% (36, 37) . In our assay a similar level of inhibition could be achieved with 1400-fold less 27-mer (70 nM), a peptide concentration that is ~60-fold less than the SAA1.1 concentration (4.2 µM) used to generate AA-amyloid in culture.
The concentrations of IAPP and Aβ used in the aforementioned studies ranged from 10 to 100 µM, which is far in excess of their normal physiological concentrations. Even in AD brains, Aβ remains in the nanomolar range (81) (82) (83) . In fact, it has been reported that little or no Aβ fibrillogenesis can take place below 14 µM (84). However, HS is known to promote fibrillogenesis of both Aβ (21) and IAPP (22) in vitro, and plaque-rich tissue extracts, which contain HS, could induce fibril assembly of nanomolar concentrations of Aβ (83) . Our data clearly demonstrate that SAA1.1:HS interactions are fundamental to AA-amyloidogenesis and suggest that peptides corresponding to other amyloidprecursor HS binding sites may be a highly successful effective strategy in the prevention of these devastating amyloid-based diseases. (69, 85) . SAA also contributes by binding to its cell surface receptor (manuscript in preparation) while the importance of its affinity for HS is unclear. SAA1.1 dissociates from HDL and in association with HS re-folds to increase its β-sheet content. These amyloidogenic intermediates then oligomerize to form a nucleating protofibril with AEF activity. Further polymerization takes place more rapidly from the ends of the protofibrils by the sequential addition of amyloidogenic SAA1.1 monomers. Proteolytic trimming of SAA takes place post-deposition and HS remains associated with the fibril stabilizing its structure.
